The Drug Eluting Technology Show

About the Program

The Drug Eluting Technology Show is a full educational program featuring a panel of experts and key opinion leaders, aiming to raise awareness about drug-eluting technologies. These have emerged as effective and safe options for treating PAD, especially compared to POBA or bare-metal stents.

Join us for this must-attend event, where cutting-edge insights, real-world case discussions, and interactive sessions will help shape the future of vascular interventions.

Program Opening

PART I – Drug Eluting Technology: Where We Stand Now

• Paclitaxel Safety – Latest findings, FDA updates, and clinical implications.
• DES & DCB Benefits Over BMS and POBA – Long-term outcomes, restenosis rates, and clinical evidence.
• The Restenosis Challenge – Prevention strategies and case studies.
• Dealing with Complex Cases – DES vs. DCB optimal strategy in multidisciplinary treatments.

PART II – Live Case Procedure from UK

PART III – Sharing Experiences & Best Practices

This program is supported by an unrestricted educational grant from

Accreditation

This activity has been accredited by the European Board for Accreditation of Continuing Education for Health Professionals (EBAC®).

Through an agreement between the European Board for Accreditation of Continuing Education for Health Professionals and the American Medical Association, physicians may convert EBAC® CE credits to AMA PRA Category 1 Credits™. Information on the process to convert EBAC credit to AMA credit can be found on the AMA website.

EBAC Standard Evaluation Form